Endovascular treatment for acute ischemic stroke [3]

New England Journal of Medicine

Volumn 368, Issue 25, 2013, Pages 2431-

  Arnold, Marcel ^a   Schroth, Gerhard ^a   Gralla, Jan ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CLINICAL EFFECTIVENESS; ENDOVASCULAR SURGERY; HUMAN; LETTER; MEDICAL DEVICE; PRIORITY JOURNAL; STENT; TREATMENT FAILURE; CEREBROVASCULAR ACCIDENT; FEMALE; MALE; METHODOLOGY; NEUROIMAGING; NOTE; THROMBECTOMY;

ENDOVASCULAR PROCEDURES; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; NEUROIMAGING; STROKE; THROMBECTOMY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84879093340     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1304759     Document Type: Letter

References (2)

1. Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet 2012;380:1241-9.
2. Nogueira RG, Lutsep HL, Gupta R, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet 2012;380:1231-40. [Erratum, Lancet 2012;380:1230.]